Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9378(62)90686-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antigen targeting and anti-tumor activity of a novel anti-CD146 Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma.
Sci Rep
October 2024
Oncoinvent ASA, 0484, Oslo, Norway.
Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of a radioimmunoconjugate to locally target mesothelioma cancer cells has been proposed as a treatment. CD146, upregulated in mesothelioma but not in healthy tissues, is a promising therapeutic target.
View Article and Find Full Text PDFA Novel Single-Step-Labeled Pb-CaCO Microparticle for Internal Alpha Therapy: Preparation, Stability, and Preclinical Data from Mice.
Materials (Basel)
November 2021
Oncoinvent AS, 0484 Oslo, Norway.
Lead-212 is recognized as a promising radionuclide for targeted alpha therapy for tumors. Many studies of Pb-labeling of various biomolecules through bifunctional chelators have been conducted. Another approach to exploiting the cytotoxic effect is coupling the radionuclide to a microparticle acting as a carrier vehicle, which could be used for treating disseminated cancers in body cavities.
View Article and Find Full Text PDFRing Versus Ovoids and Intracavitary Versus Intracavitary-Interstitial Applicators in Cervical Cancer Brachytherapy: Results From the EMBRACE I Study.
Int J Radiat Oncol Biol Phys
April 2020
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Purpose: The aim of this study was to investigate the influence of brachytherapy technique and applicator type on target dose, isodose surface volumes, and organ-at-risk (OAR) dose.
Methods And Materials: Nine hundred two patients treated with tandem/ovoids (T&O) (n = 299) and tandem/ring (T&R) (n = 603) applicators from 16 EMBRACE centers were analyzed. Patients received external beam radiation therapy and magnetic resonance imaging guided brachytherapy with dose prescription according to departmental practice.
Therapeutic Effect of α-Emitting Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer.
Transl Oncol
April 2018
Oncoinvent AS, Oslo, Norway.
Background: Ovarian cancer patients with chemotherapy-resistant residual microscopic disease in the peritoneal cavity have a considerable need for new treatment options. Alpha-emitting radionuclides injected intraperitoneally may be an attractive therapeutic option in this situation as they are highly cytotoxic, while their short range in tissues can spare surrounding radiosensitive organs in the abdomen. Herein we evaluate the therapeutic efficacy of a novel α-emitting compound specifically designed for intracavitary radiation therapy.
View Article and Find Full Text PDFThe American College of Radiology and the American Brachytherapy Society practice parameter for the performance of low-dose-rate brachytherapy.
Brachytherapy
August 2017
Department of Radiation Physics, Anderson Cancer Center, Houston, TX, USA.
Brachytherapy is the use of radionuclides to treat malignancies or benign conditions by means of a radiation source placed close to or into the tumor or treatment site. This practice parameter refers only to the use of radionuclide brachytherapy. Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!